Search

Your search keyword '"SENNIK, DEVESH K."' showing total 9 results
Start Over Author "SENNIK, DEVESH K."
9 results on '"SENNIK, DEVESH K."'

1. 756-P: The Effect of Semaglutide on Alanine Aminotransferase (ALT) Levels: Results from the Association of British Clinical Diabetologists (ABCD) Audit

Author

CRABTREE, THOMAS S.J., primary, SENNIK, DEVESH K., additional, BICKERTON, ALEX, additional, BARNES, DENNIS, additional, SIVAPPRIYAN, SIVA, additional, ADAMSON, KAREN, additional, PHILLIPS, SUZANNE M., additional, EVANS, ALISON, additional, LARSEN, NIELS, additional, PANESAR, AVINASH, additional, CULL, MELISSA L., additional, GALLEN, IAN W., additional, IDRIS, ISKANDAR R., additional, and RYDER, ROBERT E., additional

Published
2022
Full Text
View/download PDF

3. 1110-P: Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 Inhibitors (SGLT2i)

Author

DESHMUKH, HARSHAL, primary, BICKERTON, ALEX, additional, PHILLIPS, SUZANNE M., additional, EVANS, ALISON, additional, RAGHAVAN, RAJEEV P., additional, SENNIK, DEVESH K., additional, ROHILLA, ANURITA, additional, ADAMSON, KAREN, additional, YADAGIRI, MAHENDER, additional, GALLEN, IAN W., additional, RYDER, ROBERT E., additional, and SATHYAPALAN, THOZHUKAT, additional

Published
2020
Full Text
View/download PDF

4. 2224-PUB: The Effect of Diabetes Duration on Response to Empagliflozin: Data from the Association of British Clinical Diabetologists (ABCD) Audit Programme

Author

CRABTREE, THOMAS S.J., primary, ADAMSON, KAREN, additional, BICKERTON, ALEX, additional, PHILLIPS, SUZANNE M., additional, EVANS, ALISON, additional, ROBINSON, ANTHONY M., additional, ATKIN, MARC, additional, MORRIS, DAVID S., additional, WILLIAMS, DAVID M., additional, STEPHENS, JEFFREY W., additional, SENNIK, DEVESH K., additional, ROHILLA, ANURITA, additional, CULL, MELISSA L., additional, RAGHAVAN, RAJEEV P., additional, YADAGIRI, MAHENDER, additional, GALLEN, IAN W., additional, and RYDER, ROBERT E., additional

Published
2020
Full Text
View/download PDF

5. 1104-P: Many Benefits of Empagliflozin Persist in Those with Reduced Renal Function: Updated Data from the Association of British Clinical Diabetologists (ABCD) Audit Programme

Author

CRABTREE, THOMAS S.J., primary, ADAMSON, KAREN, additional, BICKERTON, ALEX, additional, PHILLIPS, SUZANNE M., additional, EVANS, ALISON, additional, ROBINSON, ANTHONY M., additional, ATKIN, MARC, additional, MORRIS, DAVID S., additional, WILLIAMS, DAVID M., additional, STEPHENS, JEFFREY W., additional, SENNIK, DEVESH K., additional, ROHILLA, ANURITA, additional, CULL, MELISSA L., additional, RAGHAVAN, RAJEEV P., additional, YADAGIRI, MAHENDER, additional, GALLEN, IAN W., additional, and RYDER, ROBERT E., additional

Published
2020
Full Text
View/download PDF

6. 1105-P: The Effect of Canagliflozin on Alanine Aminotransferase (ALT) Levels: Data from the Association of British Clinical Diabetologists (ABCD) Nationwide Audit Programme

Author

CRABTREE, THOMAS S.J., primary, PHILLIPS, SUZANNE M., additional, EVANS, ALISON, additional, SENNIK, DEVESH K., additional, ROHILLA, ANURITA, additional, BICKERTON, ALEX, additional, DARZY, KEN H., additional, WINOCOUR, PETER, additional, CULL, MELISSA L., additional, STRZELECKA, ANNA, additional, RAGHAVAN, RAJEEV P., additional, GALLEN, IAN W., additional, YADAGIRI, MAHENDER, additional, and RYDER, ROBERT E., additional

Published
2020
Full Text
View/download PDF

7. 1201-P: Characteristics and Treatment Outcomes of Patients Treated with Empagliflozin in the ABCD Nationwide Empagliflozin Audit

Author

THONG, KEN, primary, CHUNG-WAH-CHEONG, JONATHAN, additional, YADAGIRI, MAHENDER, additional, CULL, MELISSA L., additional, BICKERTON, ALEX, additional, PHILLIPS, SUZANNE M., additional, EVANS, ALISON, additional, SENNIK, DEVESH K., additional, ROHILLA, ANURITA, additional, REID, HAZEL, additional, MORRIS, DAVID S., additional, ATKIN, MARC, additional, ROBINSON, ANTHONY M., additional, WILLIAMS, DAVID M., additional, STEPHENS, JEFFREY W., additional, ADAMSON, KAREN, additional, GALLEN, IAN W., additional, and RYDER, ROBERT E., additional

Published
2019
Full Text
View/download PDF

8. 1200-P: Predictors of Glycaemic and Weight Response to Empagliflozin Treatment: The ABCD Nationwide Empagliflozin Audit

Author

THONG, KEN, primary, CHUNG-WAH-CHEONG, JONATHAN, additional, YADAGIRI, MAHENDER, additional, CULL, MELISSA L., additional, BICKERTON, ALEX, additional, PHILLIPS, SUZANNE M., additional, EVANS, ALISON, additional, SENNIK, DEVESH K., additional, ROHILLA, ANURITA, additional, REID, HAZEL, additional, MORRIS, DAVID S., additional, ATKIN, MARC, additional, ROBINSON, ANTHONY M., additional, WILLIAMS, DAVID M., additional, STEPHENS, JEFFREY W., additional, GALLEN, IAN W., additional, ADAMSON, KAREN, additional, and RYDER, ROBERT E., additional

Published
2019
Full Text
View/download PDF

9. 1209-P: Relationship between Canagliflozin Treatment Response and Duration of Diabetes: The Association of British Clinical Diabetologists (ABCD) Nationwide Canagliflozin Audit.

Author

RYDER, ROBERT E.J., PHILLIPS, SUZANNE M., EVANS, ALISON, SENNIK, DEVESH K., ROHILLA, ANURITA, BICKERTON, ALEX, THONG, KEN, YADAGIRI, MAHENDER, CULL, MELISSA L., WYRES, MELANIE C., WINOCOUR, PETER, DARZY, KEN H., STRZELECKA, ANNA, GOHIL, SHAILESH G., GALLAGHER, ALISON, and GALLEN, IAN W.

Abstract

In the ABCD nationwide liraglutide audit the impact of liraglutide on HbA1c was found to lessen with increasing duration of diabetes (abstract 1038-P, ADA 2012). We were interested to examine the relationship between change in HbA1c and duration of diabetes in response to canagliflozin in real clinical use in the ABCD nationwide canagliflozin audit. By December 2018 the audit had accumulated data on 972 canagliflozin treated patients of whom there were 604 with baseline HbA1c ≥ 7% and follow-up HbA1c (mean ± SD age 60.3 ± 11.1 year, BMI 33.7 ± 6.7 kg/m2, 62% male, median (IQR) diabetes duration 6.0 (2.6-11) year). By 1st return to clinic after commencing canagliflozin at median (IQR) 4.1 (3.0-6.1) months, mean ± SD HbA1c fell by 0.91 ± 1.2%, from 9.2 ± 1.5 to 8.3 ± 1.3% (p<0.001). Patients with duration of diabetes data (n=434) were divided into 3 groups: 0-5, 6-10, >10 years with mean ± SD baseline HbA1c 9.1 ± 1.6, 9.2 ± 1.5 and 9.3 ± 1.3% respectively (p=0.62). The mean ± SD falls in HbA1c for the 3 groups were 0.87 ± 1.3%, 0.88 ± 1.2%, and 0.86 ± 1.2%, respectfully (p=0.99) (Figure). There was thus no relationship between duration of diabetes and fall in HbA1c in this audit of canagliflozin in real clinical use in the UK. This result contrasts with that from the ABCD liraglutide audit and is in keeping with the differing modes of action of liraglutide and canagliflozin. Disclosure: R.E.J. Ryder: Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Bioquest. S.M. Phillips: None. A. Evans: None. D.K. Sennik: Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Sanofi. A. Rohilla: None. A. Bickerton: Employee; Self; MyWay Digital Health. K. Thong: None. M. Yadagiri: None. M.L. Cull: None. M.C. Wyres: None. P. Winocour: None. K.H. Darzy: None. A. Strzelecka: None. S.G. Gohil: None. A. Gallagher: Speaker's Bureau; Self; Novo Nordisk A/S. I.W. Gallen: None. Funding: Association of British Clinical Diabetologists [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results